| Document |
Document Title |
|
WO/2023/016576A1 |
A BCMA-targeted single-chain antibody and a chimeric antigen receptor based thereon and an applications thereof. Provided is a fully human and mouse single-chain antibody that specifically bind to a BCMA. The chimeric antigen receptor co...
|
|
WO/2023/016129A1 |
Provided in the present invention are a new chimeric antigen receptor that specifically binds to EPHA2, and the use thereof.
|
|
WO/2023/019251A1 |
Disclosed herein are methods and compositions for modulating immune responses by using decoy molecules to bind to soluble or other ligands. In specific embodiments, the decoy molecules comprise a domain that binds to a target immunosuppr...
|
|
WO/2023/016419A1 |
The present invention relates to a recombinant protein, the recombinant protein comprising a spacer peptide and a recombinant Ganoderma lucidum immunoregulatory protein mutant (rLZ-8 mutant); compared with the amino acid sequence shown i...
|
|
WO/2023/016524A1 |
A combined HER2 and MESO dual-target CAR-T vector, a construction method therefor and an application thereof in cancer are provided; specifically, a bispecific chimeric antigen receptor (CAR) containing HER2 scFv and MESO scFv, a 4-1BB c...
|
|
WO/2023/016247A1 |
Disclosed in the present invention is a targeting exosome for delivering RNAs. The construction process of the exosome comprises the following steps: fusing, at C-terminus, an exosome polypeptide with an RNA binding polypeptide identifyi...
|
|
WO/2023/016514A1 |
A modified cell, a method for preparing a modified cell, and a use thereof in treatment of a disease. The modified cell comprises a polynucleotide that codes a presenting peptide, wherein the polynucleotide is under the transcriptional r...
|
|
WO/2023/015759A1 |
An adenine base editor fusion protein free of limit by PAM, and an application. Provided is a mutant polypeptide. From N-terminus to C-terminus, the polypeptide sequentially comprises a SpRY(D10A) N-terminal fragment, a TadA8e fragment, ...
|
|
WO/2023/011575A1 |
Provided are a fusion protein containing a recognition function domain, a recruitment function domain, an activation function domain, and an auxiliary killing function domain, a construction method therefor and an application thereof in ...
|
|
WO/2023/015190A1 |
In various aspects and embodiments, the invention provides a method of controlling at least one cellular process in a mammalian cell via self-assembly of a synthetic organelle from expression of a scaffold protein capable of undergoing l...
|
|
WO/2023/011638A1 |
The present invention relates to a fusion protein and a use method thereof. The fusion protein comprises a first protein and a second protein; the first protein is Cas, such as Cas9, Cas12a, Cas12b, Cas12e and TALEN or ZFN; the second pr...
|
|
WO/2023/011614A1 |
Provided are an anti-PD-L1 nanobody and the use thereof. The anti-PD-L1 nanobody contains CDR1, CDR2 and CDR3, wherein CDR1 contains a sequence selected from SEQ ID NOs: 1, 5 and 9, CDR2 contains a sequence selected from SEQ ID NOs: 2, 6...
|
|
WO/2023/013619A1 |
The present invention provides an antibody that binds to a linker in a novel binding manner. More specifically, the present invention provides: an antibody that binds to a linking part between a first region and a linker in an scFv struc...
|
|
WO/2023/280307A9 |
Provided is modified immune cells expressing a mutant IL-15 polypeptide. In some embodiments, the modified immune cell further comprises an engineered receptor such as a chimeric antigen receptor (CAR). Also provided methods and pharmace...
|
|
WO/2023/011662A1 |
Provided are an anti-Her-2 antibody-granulocyte regulatory factor fusion protein, a preparation method therefor and an application thereof. Specifically, this relates to a fusion protein, a single chain of the fusion protein comprising t...
|
|
WO/2023/014931A1 |
The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclo...
|
|
WO/2023/015239A1 |
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors...
|
|
WO/2023/006131A1 |
The invention relates to a recombinant chimeric antigen comprising, in the polypeptide chain thereof, a polypeptide corresponding to amino acids 2 to 104 of the Zika virus capsid protein or a polypeptide with an amino acid sequence with ...
|
|
WO/2023/005859A1 |
A T cell receptor (TCR), having the characteristic of binding a AQIPEKIQK (SEQ ID NO: 34)-HLAA 1101 complex. Disclosed are a multivalent TCR complex, a nucleic acid molecule encoding the TCR, a vector containing nucleic acids, a cell exp...
|
|
WO/2023/005680A1 |
Provided are a human interleukin-2 variant and the use thereof. Specifically, provided is an IL-2 variant (or a derivative thereof) having eliminated or reduced affinity with a high-affinity receptor IL-2Rα/β/γ and retaining affinity ...
|
|
WO/2023/008515A1 |
The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a molecule recognizing a cancer cell or the like and a streptavidin variant. Accordi...
|
|
WO/2022/016270A9 |
The present disclosure provides fusion proteins with a multifunctional biologic design for programmed target engagement. In certain embodiments, the fusion proteins described herein provide for concurrent target antigen engagement and im...
|
|
WO/2023/010038A1 |
Some embodiments of the methods and compositions provided herein include methods and/or systems for increasing an activity of a cell comprising a chimeric antigen receptor (CAR), comprising use of a first nucleic acid encoding a transcri...
|
|
WO/2023/006117A1 |
Provided herein are antibodies and antigen-binding fragment thereof targeting CLL1, and chimeric antigen receptors (e.g., monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-CLL1 antigen-binding fragment...
|
|
WO/2023/006062A1 |
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, com...
|
|
WO/2023/005219A1 |
Provided are a chimeric antigen receptor modified by ubiquitin coupling and an immune cell. The ubiquitin is coupled to a C-terminus of the chimeric antigen receptor, and is suitable for a variety of current CAR-T cell production technol...
|
|
WO/2023/280133A9 |
A fusion protein and an application thereof, the fusion protein containing a human GLP-1 polypeptide variant and an immunoglobulin Fc region; compared to the amino acid sequence shown in SEQ ID NO: 2, the amino acid sequence of the human...
|
|
WO/2023/006082A1 |
Disclosed is an antigen targeting, anti-CD16A, and immune effector cell activating trifunctional fusion protein, comprising: a CD16A binding region that specifically binds to CD16A, a tumor-associated antigen (TAA) binding region that sp...
|
|
WO/2023/006348A1 |
The invention relates to protein building block named the Self-Assembling Kelch (SAKe) protein. The protein has a stable, symmetric design with readily accessible loops that can be varied in both sequence and length to later bind larger ...
|
|
WO/2023/004368A1 |
This disclosure relates to linker polypeptides. In some embodiments, the linker polypeptide comprises a first targeting sequence; a second targeting sequence; and a first linker between the first targeting sequence and the second targeti...
|
|
WO/2023/003464A1 |
The invention relates to the field of protein engineering and biocatalysis, in particular to methods for oxygenation of aliphatic alkenes and terpenes using bacterial enzymes. Provided is a method for oxyfunctionalization of a substrate ...
|
|
WO/2023/000170A1 |
Provided is a mouse monoclonal anti-human CD147 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5, or VH having the amino acid of SEQ ID ...
|
|
WO/2023/002952A1 |
The present invention relates to fusion proteins comprising a ligand binding domain, a protease cleavage site, and a ligand moiety. The fusion proteins of the invention comprise a ligand binding domain, a ligand moiety, and a protease cl...
|
|
WO/2023/284371A1 |
Provided in the present invention are a KHL polypeptide, and the use thereof in the preparation of a TABP-EIC cell. In addition, also provided in the present invention are a KHL polypeptide conjugate, a tumor-antigen-binding polypeptide ...
|
|
WO/2023/286694A1 |
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the dev...
|
|
WO/2023/284380A1 |
Provided is a clinical application of cells as vectors for gene therapy. Exosomes are used as primary vectors to load RNAs required for treatment, autologous or allogeneic mature somatic cells having high clinical safety or precursor cel...
|
|
WO/2023/284053A1 |
A chimeric antigen receptor targeting mesothelin, and the use thereof. The chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular domain which are sequentially linked, wherein the extrace...
|
|
WO/2023/288296A1 |
Provided herein are chimeric hMPV/RSV F proteins. In some aspects, the chimeric hMPV/RSV F proteins exhibit enhanced conformational stability, enhanced thermostability, and/or increased expression. Methods are also provided for use of th...
|
|
WO/2023/284733A1 |
The present invention relates to the field of biomedicine, and provides a GITR/TGF-β dual-targeted fusion protein, a conjugate and pharmaceutical composition comprising same, and a use of the fusion protein or conjugate in the preparati...
|
|
WO/2023/284700A1 |
A novel chimeric receptor composition, a recombinant vector, a cell, and an application thereof. The novel chimeric receptor composition comprises a conventional chimeric antigen receptor (CAR), and an NKG2D chimeric receptor comprising ...
|
|
WO/2023/284684A1 |
A milk-derived polypeptide derivative and applications thereof in the preparation of a drug, a health product and a food additive for the prevention and treatment of obesity, belonging to the technical field of biomedicine. The present m...
|
|
WO/2023/286766A1 |
The present invention provides a polypeptide containing an amino acid sequence (region 1) that specifically binds to a constant site of an antibody and an amino acid sequence (region 2) that specifically binds to a nucleic acid.
|
|
WO/2023/284889A1 |
The present application relates to the field of genetic engineering, specifically to a CLD protein mutant and the use thereof. The CLD protein mutant is as shown in SEQ ID NO. 4. According to the present invention, cysteine at position 6...
|
|
WO/2023/283736A1 |
Homologous dimerization (HD) peptides are described having improved self-binding. The HD peptides may comprise an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide or comprise...
|
|
WO/2023/284471A1 |
The present invention relates to a novel polypeptide for specific recognition of a prostate cancer cell, and a derivative and the use thereof. The polypeptide is obtained by means of screening a phage-polypeptide library, can specificall...
|
|
WO/2023/286841A1 |
Provided are: a chimeric antigen receptor comprising a target antigen binding region, a transmembrane region and a signal transduction region, in which the transmembrane region contains, at the C-terminal thereof, a first polypeptide sel...
|
|
WO/2023/284822A1 |
Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. P...
|
|
WO/2023/286059A1 |
Compositions and methods for treating a medical condition are provided. Accordingly, there is provided a composition comprising a polypeptide comprising a GnRH receptor binding protein and a polynucleotide coding a therapeutic agent, whe...
|
|
WO/2023/286840A1 |
An anti-EGFRviii antibody that is an antibody having a specific CDR sequence and is selected from the group consisting of the antibodies (a-1) to (a-3); a polypeptide comprising the antibody; a cell capable of expressing the polypeptide;...
|
|
WO/2023/288281A2 |
The present disclosure provides fusion proteins with novel signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component that is capable of binding to a TGFβ polypeptide, a transmembrane co...
|
